Osteoporosis in Women vs Men: Key Differences

The widespread perception of osteoporosis as primarily a women's condition reflects an important truth alongside a substantial misunderstanding. Women do face higher osteoporosis risk than men, with prevalence rates approximately 4 times higher in women than men in most age groups. Yet approximately 1 in 5 men over age 50 will experience an osteoporotic fracture during their remaining lifetime, and the mortality after hip fracture is actually higher in men than in women — first-year mortality approaching 30 to 35 percent in men compared to 20 to 25 percent in women.

The differences between osteoporosis in women and men extend beyond prevalence to include timing of disease development, contributing factors, presentation patterns, and treatment considerations. Both groups benefit from appropriate screening based on risk factors, recognition of symptoms when they develop, and effective treatment when osteoporosis is identified.

For more on testing, see Osteoporosis: Causes, Symptoms, Diagnosis, Fracture Risk, and Treatment (Complete Guide).

⸻

Prevalence Differences

Women

Approximately 1 in 3 women over age 50 will experience an osteoporotic fracture during their remaining lifetime. The prevalence of osteoporosis (T-score of −2.5 or lower) is approximately 20 percent in women over age 50 and increases substantially with age.

Men

Approximately 1 in 5 men over age 50 will experience an osteoporotic fracture during their remaining lifetime. The prevalence of osteoporosis is approximately 5 percent in men over age 50, with substantial increases at older ages. The prevalence in men is somewhat masked by lack of routine screening compared to women.

Why the Difference

Women have lower peak bone mass than men, experience accelerated bone loss after menopause due to estrogen deficiency, and live longer on average — all contributing to higher overall prevalence.

For more on testing, see Bone Density Test (DXA): What It Is and How to Read Results.

⸻

Hormonal Factors

Estrogen and Women's Bone Health

Estrogen plays a central role in maintaining bone density in women. During reproductive years, estrogen suppresses bone resorption (breakdown). After menopause, estrogen levels decrease substantially, triggering accelerated bone loss. The first 5 to 10 years after menopause involve the most rapid bone loss, with women losing approximately 1 to 5 percent of bone density per year. Early menopause (before age 45) extends this period of accelerated loss; surgical menopause produces a particularly abrupt estrogen decline.

Testosterone and Men's Bone Health

Testosterone plays a role in maintaining bone density in men, though the effect is less dramatic than estrogen in women. Testosterone declines gradually with age rather than abruptly. Hypogonadism (testosterone deficiency) substantially increases osteoporosis risk in men. Estrogen is also important for bone health in men — it comes from conversion of testosterone — though at much lower levels than in women.

Hormonal Therapies and Bone Health

In women, hormone replacement therapy (HRT) can affect bone density positively, while aromatase inhibitors for hormone-positive breast cancer reduce bone density. In men, androgen deprivation therapy for prostate cancer reduces bone density substantially.

For more on causes, see What Causes Osteoporosis? Risk Factors Explained.

⸻

Age of Disease Development

Bone loss accelerates in women at menopause, typically around age 50 — many women develop osteoporosis in their 60s. Men experience more gradual bone loss starting at later ages, with significant bone loss typically beginning after age 60 to 65 and osteoporosis often developing in their 70s or later. This affects screening timing: for women, screening typically begins around age 65 or earlier with risk factors; for men, typically around age 70 or earlier with substantial risk factors.

For more on prevention, see How to Prevent Osteoporosis: Lifestyle and Nutrition.

⸻

Risk Factors by Gender

Risk Factors Particularly Affecting Women

Menopause (particularly early or surgical menopause), history of pregnancy and breastfeeding, various reproductive conditions, eating disorders (particularly anorexia nervosa), and smaller body frame.

Risk Factors Particularly Affecting Men

Hypogonadism (testosterone deficiency), androgen deprivation therapy for prostate cancer, and various male-specific conditions.

Risk Factors Affecting Both

Family history of osteoporosis, previous fragility fractures, long-term corticosteroid use, various other medications, smoking, excessive alcohol consumption, sedentary lifestyle, inadequate calcium and vitamin D, and various medical conditions including endocrine disorders, gastrointestinal conditions, and chronic kidney disease.

For more on secondary causes, see Secondary Osteoporosis: Causes and When to Suspect It.

⸻

Differences in Presentation

Women often present at an earlier age (typically 60s and 70s), with a higher proportion of vertebral fractures and wrist fractures particularly common in younger postmenopausal women. Men often present at older ages (typically 70s and 80s), with a higher proportion of hip fractures, often more severe fractures, and sometimes multiple fractures at presentation. When symptoms occur, they are similar in both genders — both face the substantially silent nature of the disease.

For more on symptoms, see Symptoms of Osteoporosis: Early Signs You Should Not Ignore.

⸻

Outcomes After Fractures

Hip fracture mortality is higher in men than women: first-year mortality is approximately 20 to 25 percent in women and approximately 30 to 35 percent in men. The reasons include older age at fracture in men, more comorbidities at time of fracture, and various other factors. Functional decline after fractures tends to be more substantial in men, and loss of independence affects both genders significantly.

For more on risk assessment, see T-Score and FRAX: How Fracture Risk Is Calculated.

⸻

Why Men Are Often Missed

Several factors contribute to underdiagnosis of osteoporosis in men: widespread perception of osteoporosis as a women's disease (affecting both patients and providers), less routine screening compared to postmenopausal women, atypical presentations, and later disease development where symptoms occur at older ages when various other conditions compete for attention. The underdiagnosis means many men with osteoporosis remain unidentified until fractures occur.

For more on related considerations, see Most Commonly Misdiagnosed Conditions.

⸻

Screening Recommendations

For women, screening generally includes DXA starting at age 65 for all women, or earlier after menopause for those with risk factors. For men, recommendations are less standardized but generally include DXA starting at age 70, or earlier for those with substantial risk factors. Various risk factors modify recommendations for both genders. Women typically receive more consistent screening than men in practice.

For more on testing, see Bone Density Test (DXA): What It Is and How to Read Results.

⸻

Treatment Considerations

Shared Approaches

Lifestyle approaches including adequate calcium and vitamin D, weight-bearing exercise, smoking cessation, and limited alcohol consumption apply similarly to both genders. Bisphosphonates are typically first-line treatment for both (alendronate, risedronate, ibandronate, zoledronic acid have demonstrated efficacy in both). Denosumab (Prolia) is approved for both. Anabolic therapies including teriparatide and abaloparatide are approved for both.

Hormone-Specific Treatments

In women: hormone replacement therapy (HRT) for selected patients and selective estrogen receptor modulators (SERMs) such as raloxifene. In men: testosterone replacement for hypogonadal men, though specific osteoporosis treatments may also be needed. Romosozumab is approved for postmenopausal women but has limited use in men.

For more on prevention, see How to Prevent Osteoporosis: Lifestyle and Nutrition.

⸻

Special Considerations for Women

Menopause management (including HRT in selected patients) addresses both menopausal symptoms and bone health. Pregnancy and breastfeeding affect bone density temporarily — most women recover bone density after these phases. Eating disorders require treatment of the underlying disorder as essential. Reproductive conditions such as premature ovarian insufficiency affect bone health. Cancer treatments including aromatase inhibitors for breast cancer warrant specific monitoring and treatment.

⸻

Special Considerations for Men

Hypogonadism evaluation is appropriate in many men with osteoporosis and supports appropriate treatment. Androgen deprivation therapy for prostate cancer warrants specific monitoring. Various chronic conditions and lifestyle factors (alcohol consumption, smoking) substantially affect men's bone health. Late recognition of osteoporosis in men makes it important to evaluate after fractures and to consider the diagnosis broadly.

For more on adult-onset disease patterns, see What Causes Osteoporosis? Risk Factors Explained.

⸻

Common Misconceptions

• Osteoporosis only affects women — It affects both genders with substantial disease burden in men.
• Men don't get osteoporotic fractures — Approximately 1 in 5 men over age 50 will experience one.
• Men recover from fractures better than women — Outcomes after hip fractures are actually worse in men.
• Treatments don't work as well in men — Most osteoporosis treatments have demonstrated efficacy in both genders.
• Only postmenopausal women need screening — Various risk factors warrant screening in younger women and in men.
• Testosterone replacement cures osteoporosis in men — It helps hypogonadal men but is not always sufficient; specific osteoporosis treatments may also be needed.

⸻

When to See a Specialist

Primary care physicians manage many patients. Endocrinologists evaluate complex cases including hormonal contributions. Rheumatologists, gynecologists, urologists, orthopedic surgeons, geriatricians, and oncologists all address their respective aspects. For complex situations, evaluation at major medical centers with comprehensive bone health programs provides specialized expertise.

⸻

Conclusion

Osteoporosis affects both women and men with important differences. Women face higher overall risk (approximately 1 in 3 women vs 1 in 5 men over age 50 experiencing an osteoporotic fracture), yet outcomes after fractures — particularly hip fractures — are actually worse in men, with first-year mortality of 30 to 35 percent compared to 20 to 25 percent in women.

Hormonal factors drive the gender differences: accelerated bone loss after menopause in women versus more gradual age-related loss in men. Women develop osteoporosis earlier (often in their 60s), men later (often in their 70s or later). Risk factors, presentation, and fracture types also differ.

Men are frequently underdiagnosed due to the widespread perception of osteoporosis as a women's disease, less routine screening, and later disease development. Treatment is generally similar in both genders, with bisphosphonates as typical first-line therapy and hormone-specific options differing between genders.

With appropriate awareness, screening, and treatment, osteoporosis can be effectively managed in both women and men. The combination of awareness, appropriate screening, and engagement with care provides the foundation for the best possible outcomes.

⸻

Medical Disclaimer

This content is for informational purposes only and does not constitute medical advice. Individuals should consult a qualified healthcare provider for diagnosis and treatment.